LU91321I2 - Particule similaire au virus HPV18 (gardasil, silgard) - Google Patents

Particule similaire au virus HPV18 (gardasil, silgard)

Info

Publication number
LU91321I2
LU91321I2 LU91321C LU91321C LU91321I2 LU 91321 I2 LU91321 I2 LU 91321I2 LU 91321 C LU91321 C LU 91321C LU 91321 C LU91321 C LU 91321C LU 91321 I2 LU91321 I2 LU 91321I2
Authority
LU
Luxembourg
Prior art keywords
protein
contg
proteins
vlps
derived
Prior art date
Application number
LU91321C
Other languages
English (en)
Original Assignee
Csl Ltd
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3775561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91321(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd, Univ Queensland filed Critical Csl Ltd
Publication of LU91321I2 publication Critical patent/LU91321I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
LU91321C 1991-07-19 2007-03-09 Particule similaire au virus HPV18 (gardasil, silgard) LU91321I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPK732291 1991-07-19

Publications (1)

Publication Number Publication Date
LU91321I2 true LU91321I2 (fr) 2007-05-09

Family

ID=3775561

Family Applications (8)

Application Number Title Priority Date Filing Date
LU91318C LU91318I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV 16
LU91316C LU91316I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV11
LU91315C LU91315I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6
LU91317C LU91317I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6,HPV11,HPV16 et HPV18
LU91321C LU91321I2 (fr) 1991-07-19 2007-03-09 Particule similaire au virus HPV18 (gardasil, silgard)
LU91386C LU91386I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV18
LU91385C LU91385I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV16
LU91387C LU91387I2 (fr) 1991-07-19 2007-12-14 CERVARIX - La combinaison des particules similaires au virus HPV16 et HPV18

Family Applications Before (4)

Application Number Title Priority Date Filing Date
LU91318C LU91318I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV 16
LU91316C LU91316I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV11
LU91315C LU91315I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6
LU91317C LU91317I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6,HPV11,HPV16 et HPV18

Family Applications After (3)

Application Number Title Priority Date Filing Date
LU91386C LU91386I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV18
LU91385C LU91385I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV16
LU91387C LU91387I2 (fr) 1991-07-19 2007-12-14 CERVARIX - La combinaison des particules similaires au virus HPV16 et HPV18

Country Status (17)

Country Link
US (5) US7476389B1 (fr)
EP (5) EP0595935B1 (fr)
JP (3) JP3828570B2 (fr)
KR (1) KR100240480B1 (fr)
AT (3) ATE356142T1 (fr)
AU (1) AU651727B2 (fr)
CA (1) CA2113712C (fr)
CY (5) CY2598B2 (fr)
DE (11) DE122007000084I1 (fr)
DK (3) DK1359156T3 (fr)
ES (3) ES2279020T3 (fr)
GE (1) GEP20084431B (fr)
HK (1) HK1059271A1 (fr)
LU (8) LU91318I2 (fr)
NL (8) NL300262I1 (fr)
SG (1) SG48769A1 (fr)
WO (1) WO1993002184A1 (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595935B1 (fr) 1991-07-19 2003-03-19 The University Of Queensland Vaccin contre le virus du Papillome
WO1994000152A1 (fr) * 1992-06-25 1994-01-06 Georgetown University Vaccin contre le papillomavirus
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AU688759C (en) * 1993-03-09 2006-12-21 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
EP0757717B1 (fr) * 1994-05-16 2006-05-31 Merck & Co. Inc. Vaccins contre le papillomavirus
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
DE122007000092I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
DE4435907C2 (de) * 1994-10-07 1997-07-24 Lutz Prof Dr Gissmann Papillomavirusähnliche Partikel und deren Anwendung
DE19526752C2 (de) * 1995-07-21 1997-08-07 Lutz Prof Dr Gissmann Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
EP0812358A1 (fr) * 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
SE9501512D0 (sv) * 1995-04-24 1995-04-24 Euro Diagnostica Ab Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
EP0863982B1 (fr) * 1995-11-15 2004-01-21 Merck & Co., Inc. Particules synthetiques de type viral hpv11
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ATE256734T1 (de) * 1996-10-04 2004-01-15 Merck & Co Inc Synthetische hpv16 virus-ähnliche partikel
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
DE69727830T2 (de) * 1996-12-09 2004-10-07 Merck & Co Inc Synthetische hpv-16 virusähnliche partikel
EP0957936B1 (fr) * 1996-12-20 2006-10-04 MERCK & CO., INC. Formulations de vaccins a base de papillonavirus recombine
EP0980257A1 (fr) * 1997-05-01 2000-02-23 Chiron Corporation Utilisation de particules de type viral en tant qu'adjuvants
CA2295316C (fr) * 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
KR100785397B1 (ko) 2001-06-28 2007-12-13 아피메즈 주식회사 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
CA2457804C (fr) 2001-08-13 2012-10-16 University Of Rochester Immunisation transcutanee contre le papillomavirus avec un virus de type papillomavirus
EP1427443A4 (fr) * 2001-08-23 2006-03-08 Merck & Co Inc Vaccin mettant en oeuvre des proteines e du virus du papillome administrees par vecteur viral
KR20030067873A (ko) * 2002-02-08 2003-08-19 주식회사 유니크 솔레노이드 밸브
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP4842128B2 (ja) 2003-07-21 2011-12-21 トランジェーヌ、ソシエテ、アノニム 新規多機能性サイトカイン
EP1664348B8 (fr) 2003-09-25 2019-06-12 Third Wave Technologies, Inc. Detection de papillomavirus
EP1790332B1 (fr) * 2004-09-10 2010-07-21 Asahi Glass Company, Limited Vaccin pour administration orale contre le pappilomavirus humain
US8021992B2 (en) * 2005-09-01 2011-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. High aspect ratio gap fill application using high density plasma chemical vapor deposition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8080643B2 (en) * 2006-09-05 2011-12-20 Third Wave Technologies, Inc. HPV primers
PL2468300T3 (pl) 2006-09-26 2018-04-30 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2097517B1 (fr) 2006-10-16 2014-06-04 Genelux Corporation Virus recombinant de la vaccine de souche Lister codant pour un anticorps anti-VEGF à chaîne unique
CA2679410C (fr) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Nouveau procede et nouvelles compositions
MY162658A (en) * 2007-11-23 2017-06-30 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
EP2241626B1 (fr) * 2008-01-09 2016-01-06 Konkuk University Industrial Cooperation Corp Vaccins à base de baculovirus
US9623098B2 (en) 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
MX2011013566A (es) 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
US9322827B2 (en) 2010-04-08 2016-04-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
EP2576840B1 (fr) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Analyse de capture hybride à résultats rapides et sondes associées tronquées de manière stratégique
KR101349291B1 (ko) 2010-08-10 2014-01-10 한국생명공학연구원 고초균을 이용하여 자궁경부암 백신을 제조하는 방법
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2811981B1 (fr) 2012-02-07 2019-05-08 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
WO2013139744A1 (fr) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Procédé de vaccination contre le papillomavirus humain
ES2787455T3 (es) 2012-05-16 2020-10-16 Immune Design Corp Vacunas para el VHS-2
EP2912069B1 (fr) 2012-10-23 2019-07-31 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
US10314906B2 (en) 2015-03-18 2019-06-11 University Of Massachusetts Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
KR101908438B1 (ko) * 2016-02-05 2018-10-16 (주)피앤피바이오팜 Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
KR20180115276A (ko) 2016-02-22 2018-10-22 베링거잉겔하임베트메디카게엠베하 생체 분자의 고정화 방법
CN109562057A (zh) 2016-05-16 2019-04-02 传染病研究所 聚乙二醇化脂质体和使用方法
CN109310773B (zh) 2016-05-16 2022-04-26 传染病研究所 含有tlr激动剂的配制品和使用方法
IL311086A (en) 2016-06-01 2024-04-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
WO2018232257A1 (fr) 2017-06-15 2018-12-20 Infectious Disease Research Institute Supports lipidiques nanostructurés et émulsions stables et leurs utilisations
WO2019051149A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
US20220249646A1 (en) 2019-05-25 2022-08-11 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用
WO2022051022A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Arn co-lyophilisé et support lipidique nanostructuré
CN117222428A (zh) 2021-02-11 2023-12-12 葛兰素史克生物有限公司 Hpv疫苗生产
WO2024052882A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524487B1 (fr) 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US5071757A (en) 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
NL8902301A (nl) * 1989-09-14 1991-04-02 Rijksuniversiteit Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
WO1992016638A1 (fr) 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Vehicules de transduction pour le transfert de l'adn a une cellule de mammifere
EP0595935B1 (fr) 1991-07-19 2003-03-19 The University Of Queensland Vaccin contre le virus du Papillome
WO1994000152A1 (fr) 1992-06-25 1994-01-06 Georgetown University Vaccin contre le papillomavirus
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AU688759C (en) 1993-03-09 2006-12-21 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles

Also Published As

Publication number Publication date
EP1359156B1 (fr) 2007-03-07
ES2279020T3 (es) 2007-08-16
CY2007030I1 (el) 2012-01-25
LU91387I2 (fr) 2008-02-14
CY2007034I1 (el) 2012-01-25
EP1359156A2 (fr) 2003-11-05
NL300260I1 (nl) 2007-05-01
DE69232967D1 (de) 2003-04-24
EP1471147A2 (fr) 2004-10-27
EP1298211A2 (fr) 2003-04-02
DE69233639T2 (de) 2007-05-31
DE122007000023I1 (de) 2007-08-09
CY2598B2 (en) 2010-03-03
EP1207203A2 (fr) 2002-05-22
LU91316I2 (fr) 2007-04-27
DE69233687T2 (de) 2007-10-18
JPH07505042A (ja) 1995-06-08
CA2113712A1 (fr) 1993-02-04
EP1207203A3 (fr) 2004-04-28
NL300313I1 (nl) 2008-02-01
DE122007000085I1 (de) 2008-03-27
LU91317I2 (fr) 2007-04-27
CY2007016I1 (el) 2009-11-04
NL300312I1 (nl) 2008-02-01
JP2004000269A (ja) 2004-01-08
DE69232967T2 (de) 2003-12-18
DE69233639D1 (de) 2006-08-24
NL300261I1 (nl) 2007-05-01
NL300314I2 (nl) 2010-03-01
EP1471147A3 (fr) 2007-03-21
EP0595935A1 (fr) 1994-05-11
NL300262I1 (nl) 2007-05-01
DK1298211T3 (da) 2006-11-13
NL300266I1 (nl) 2007-05-01
JP3828570B2 (ja) 2006-10-04
US6613557B1 (en) 2003-09-02
CA2113712C (fr) 2007-06-12
DE122007000084I1 (de) 2008-03-27
DE122007000019I1 (de) 2007-07-26
CY2007015I2 (el) 2016-08-31
ES2194839T3 (es) 2003-12-01
LU91315I2 (fr) 2007-04-27
LU91385I2 (fr) 2008-02-14
US20090252761A1 (en) 2009-10-08
CY2007016I2 (el) 2009-11-04
NL300314I1 (nl) 2008-02-01
EP0595935B1 (fr) 2003-03-19
ATE356142T1 (de) 2007-03-15
CY2007015I1 (el) 2009-11-04
DE122007000017I1 (de) 2007-07-26
LU91386I2 (fr) 2008-02-14
DE69233687D1 (de) 2007-04-19
NL300263I1 (nl) 2007-05-01
DK1359156T3 (da) 2007-04-10
JP4255944B2 (ja) 2009-04-22
JP2006115849A (ja) 2006-05-11
DE122007000016I1 (de) 2007-05-24
LU91318I2 (fr) 2007-04-27
WO1993002184A1 (fr) 1993-02-04
EP1298211B1 (fr) 2006-07-12
HK1059271A1 (en) 2004-06-25
DK0595935T3 (da) 2003-07-21
ATE332973T1 (de) 2006-08-15
DE122007000086I1 (de) 2008-04-17
SG48769A1 (en) 1998-05-18
ATE234925T1 (de) 2003-04-15
DE122007000018I1 (de) 2007-05-24
KR100240480B1 (ko) 2000-03-02
US7939082B2 (en) 2011-05-10
AU651727B2 (en) 1994-07-28
AU2366692A (en) 1993-02-23
US7476389B1 (en) 2009-01-13
US20040214331A1 (en) 2004-10-28
EP1298211A3 (fr) 2003-04-16
EP1359156A3 (fr) 2004-03-24
US20070154902A1 (en) 2007-07-05
US7169585B2 (en) 2007-01-30
CY2007030I2 (el) 2017-04-05
ES2267890T3 (es) 2007-03-16
EP0595935A4 (fr) 1995-03-29
GEP20084431B (en) 2008-07-25

Similar Documents

Publication Publication Date Title
LU91321I2 (fr) Particule similaire au virus HPV18 (gardasil, silgard)
NL300324I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
DE05075369T1 (de) Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
CA2339324A1 (fr) Systeme de distribution de proteine utilisant des particules humaines de type papillomavirus